Table 1.
Clinical details of the 6 patients (RAI: Radioiodine, ER: the estrogen receptor, PR: progesterone receptor, HER2/neu: human epidermal growth factor receptor-2, LAR: long-acting)
| S.No | Age/Gender | Histopathology | Prior treatments |
|---|---|---|---|
| 1 | 45/F | Papillary thyroid cancer (RAI refractory) | Disease progression on sorafenib, radiotherapy and lenvatinib |
| 2 | 63/F | Papillary thyroid cancer (RAI refractory) | Disease progression on sorafenib, radiotherapy and lenvatinib |
| 3 | 46/F | Papillary thyroid cancer (RAI refractory) | Disease progression on sorafenib and lenvatinib |
| 4 | 56/F | ER-, PR-HER2/neu-left breast cancer | Surgery, radiotherapy and chemotherapy |
| 5 | 46/M | Pancreatic neuroendocrine cancer | Sandostatin LAR, capecitabine |
| 6 | 58/M | Duodenal neuroendocrine cancer | Sandostatin LAR, [177Lu]Lu-DOTATATE+capecitabine |